|
Session 122
Poster Abstracts
Immune-Based Therapies: Novel Approaches
Wednesday, 1-4 pm
Room: Hall A |
719
 |
Treatment of HIV-1 Infection by Allogeneic CCR5-D32/D32 Stem Cell Transplantation: A Promising Approach
Gero Hutter*, D Nowak, M Mossner, S Ganepola, K Allers, T Schneider, J Hofmann, I Blau, W K Hofmann, and E Thiel
Med Univ of Berlin, Germany |
| 720 |
Reprogramming Cellular and Humoral Immunocomponents to Kill and Neutralize HIV-1: A Novel Investigatory and Therapeutic System
Aviva Joseph*1, J Zheng1, A Follenzi2, D Katinger3, R Kunert3, B Walker4, and H Goldstein1,5
1Albert Einstein Coll of Med, Bronx, NY, US; 2Albert Einstein Coll of Med, Bronx, NY, US; 3Inst of Applied Microbio, Vienna, Austria; 4Partners AIDS Res Ctr, Massachusetts Gen Hosp, Harvard Med Sch, Boston, US; and 5Albert Einstein Coll of Med, Bronx, NY, US |
721
|
Effects of Recombinant Growth Hormone on T Cell Phenotype and Function in vitro and in vivo during Treated HIV-1 Infection
Alison Cranage*1, G Moyle2, M Bower2, B Gazzard2, F Gotch1, and N Imami1
1Imperial Coll, London, UK and 2Chelsea and Westminster Hosp, London, UK |
722
|
A Study of Leflunomide to Target Immune Activation in HIV: Results of a Pilot Study
Sarah Read*, M De Grezia, E Ciccone, R DerSimonian, W Gao, C Rehm, A Pau, R Davey, C Lane, and I Sereti
NIAID, NIH, Bethesda, MD, US |
723
|
A Specific Mixture of Prebiotic Oligosaccharides Reduces Hyper-immune Activation and Improves NK Cell Cytolytic Activity in HAART-naive HIV+ Adults
Belinda van't Land*1,2, K Benlhassan-Chahour3, G Rizzardini4, A Vriesema2, J Garssen1,2, D Trabattoni5, D Bray3, A Gori6, M Clerici5, and COPA study team
1Utrecht Inst for Pharma Sci, The Netherlands; 2Numico Res, Wageningen, The Netherlands; 3ImmunoClin, Paris, France; 4Hosp Luigi Sacco, Milan, Italy; 5Univ of Milan, Italy; and 6Hosp San Gerardo, Univ of Milan-Bicocca, Monza, Italy |
| 724 |
Evaluation of Natural Killer Cells and Expression of KIR and Lectin-like Receptors in HIV-1-infected Patients after 2 Years of Different Strategies of Structured Therapy Interruption
G Mestre1, F Garcia1, E Martinez1, A Milinkovic1, A Leon1, A Lopez1, J Lozano2, J Pena2, J Gatell1, and Montserrat Plana*1
1Hosp Clin-IDIBAPS, Univ of Barcelona, Spain and 2Hosp Reina Sofia, Cordoba, Spain |
| 725 |
Influence of Repeated Cycles of Structured Therapy Interruption on the Rate of Recovery of CD4+ T Cells after HAART Resumption
A Leon, E Martinez, A Milinkovic, B Mora, R Argelich, A Lopez, T Gallart, Montserrat Plana*, J Gatell, and F Garcia
Hosp Clin-IDIBAPS, Univ of Barcelona, Spain |
|
